Parasitic infections remain a serious public health issue globally, requiring prompt and precise diagnosis. Traditional diagnostic techniques, such as microscopic examinations, immunological methods, such as enzyme-linked immunosorbent assay (ELISA), and molecular tests, such as polymerase chain reaction (PCR), are standard tools for parasite identification. However, traditional methods are time-consuming and have less sensitivity and specificity than nanobiosensors. Hence, the current review aims to analyze the nanobiosensors in detecting globally important human parasites, i.e., Plasmodium, Leishmania, Echinococcus, Schistosoma, and Taenia, emphasizing their significance in the early detection and analyzing their future challenges. Nanobiosensors provide efficient, sensitive, and rapid diagnosis of parasites’ antigens or genetic material using nanomaterials, such as nanowires, quantum dots (QDs), metallic nanoparticles, and carbon nanotubes, as well as identification of biomarkers, including excretory–secretory products and microRNAs. Nanobiosensors can utilize diverse nanomaterials such as gold nanoparticles (AuNPs) for the detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) in Plasmodium, carbon nanotubes (CNTs) functionalized with anti-EgAgB antibodies for Echinococcus, and QDs labeled with DNA probes for the detection of Leishmania kDNA. Regarding Schistosoma, graphene oxide (GO)-based nanobiosensors with a soluble egg antigen (SEA) binding, and for Taenia, metallic nanobiosensors can detect parasites’ biomarkers even at low concentrations. Challenges for using nanobiosensors in parasitic infection diagnosis include limitations in mass production, biological matrix interference, and the need for standardization. Development of multiplex nanobiosensors using polymer nanofibers or hybrid nanoparticles for simultaneous detection of multiple pathogens, along with integration of lab-on-a-chip technology for point-of-care (PoC) platforms, is an important future prospect that needs to be worked on. In conclusion, considering the rapidly ongoing advancement of nanobiosensors, it is expected that they will aid the detection, treatment, and management of parasitic infections by providing new avenues for early detection, improved treatment, and improved disease management in the future. Graphical Abstract

Echinococcus granulosus sensu lato is a zoonotic agent with a life cycle consisting of definitive hosts (dogs and wild carnivores), and intermediate hosts (usually ungulates). Other animals and humans may accidentally ingest eggs and contract cystic echinococcosis, acting as aberrant hosts. A 3-year-old neutered female cat was brought to a veterinary practice in Sassari (Italy) with abdominal distension. Ultrasound showed multiple intraperitoneal vesicles, which on laparotomy were found to be metacestodes of E. granulosus. Videos of the extraction of cysts are provided. Phylogenetic analysis based on a fragment of the cytochrome oxidase subunit 1 (cox1) mitochondrial gene identified the isolate as E. granulosus sensu stricto genotype G1, the most common genotype circulating in Europe and the Mediterranean basin. This is the first case report of cystic echinococcosis in domestic cats from Italy.

Cystic echinococcosis (CE) is a zoonotic disease affecting humans and animals. Despite a lack of clarity about many details of parasite–intermediate host interactions, the nature of the immune responses triggered by hydatid infection has revealed new perspectives. This study discusses the latest advances in elucidating the immunologic mechanism of echinococcosis and its detection and potential approaches to enhance serodiagnosis accuracy. Moreover, nanobiosensors have been evaluated according to their potential to improve treatment efficiency and aid in an early diagnosis of cystic echinococcosis. The serum of an intermediate host can diagnose CE by analyzing antibodies induced by Echinococcus granulosus. Among the most notable features of this method are its noninvasive ability and high sensitivity, both of which make it an excellent tool for clinical diagnosis. Several serological tests, including ELISAs and immunoblotting, can detect these antibodies to assess the disease’s state and determine the treatment outcome. A thorough understanding of what cross-reactivity means and the stage of the disease are crucial to interpreting serological results. Nanobiosensors have also proven better than conventional biosensors in detecting hydatid cysts. Additionally, they are highly sensitive and versatile when detecting specific biomarkers, improving diagnostic accuracy. These immunomodulatory molecules, induced by E. granulosus, are a good candidate for diagnosing cystic echinococcosis because they alter intermediate host immune responses. Hydatid cyst detection is also enhanced through nanobiosensors, which provide better accuracy.

Echinococcus granulosus sensu lato (s.l.) is the causative agent of cystic echinococcosis in animals and humans. Different E. granulosuss.l. genotypes exhibit great diversity in their life cycle, host selectivity and pathogenicity. For this reason, the study of genetic variation within Echinococcus species is of importance for their epidemiological implication. We employed two SNP genotyping technologies to distinguish G1 and G3 E. granulosus sensu stricto (s.s.). genotypes. The genotypes of DNA samples (n = 28) extracted from hydatid cysts of different animal species were identified by amplification and sequencing of a fragment of the mitochondrial nad5 gene. Two SYBR green and three TaqMan real time PCR assays were developed for targeting of three nad5 informative positions (SNP758, 1123, and 1380) known to be able to discriminate G1 from G3. Genotyping by SYBR Green PCR based on cycle threshold (Ct) with melting temperature (Tm) analysis and performed on SNP1123 and SNP1380 failed to identify one DNA sample. TaqMan assays for SNP758, 1123 and 1380 effectively confirmed genotype identification obtained by Sanger sequencing. Our results demonstrated that the combination of the three Taqman assays developed in this study represents a valuable and cost effective tool alternative to DNA sequencing for E. granulosus s.s. genotyping.

Cystic echinococcosis still remains a serious health and economic problem worldwide. The etiologic agent is Echinococcus granulosus sensu lato, giving origin to a fluid-filled cystic lesion. Therapy faces several challenges. Nanodrugs have shown promise as chemotherapeutics against hydatid cysts. The present study evaluated a highly safe lipid nano-polymeric capsule for its superior efficacy and ability to overcome drug resistance. Nanocapsule drugs were formulated into six groups: Albendazole, mebendazole, praziquantel, albendazole + mebendazole, albendazole + praziquantel, and praziquantel + mebendazole. The protoscolicidal effects of these six groups were assessed at 10, 60, and 120 min in three concentrations (1, 0.5, and 0.25 mg/mL). Drug formulations were evaluated via zeta potential, droplet size, solubility, particle size analyzer (PSA), and scanning electron microscopy. According to the PSA results, the mean size of the albendazole nanocapsules was 193.01 nm, mebendazole was 170.40 nm, and praziquantel was 180.44 nm. Albendazole + mebendazole showed the greatest protoscolicidal activity at a concentration of 1 mg/mL after 120 min. In contrast, each drug’s 0.25 mg/mL single-dose times showed the least protoscolicidal activity after 120 min. With the right application of nanotechnology, it is possible to produce safe and effective drugs, such as the polymeric combination of albendazole and mebendazole, which has promising implications.